World Congress of Pharmacy and Pharmaceutical Sciences 2006

66th International Congress of FIP

Main Theme: Bringing Innovations into Patient Care

Salvador Bahia, Brazil, 25-31 August 2006

Congress Programme
Welcome to Bahia, for all the senses!!!

Salvador is a magic city. People try to explain its magic by its rich cultural heritage, internationally known natural beauties, hospitality of its people, the artistic and cultural melting pot that the city is and many others tangible virtues, but now that you are in Salvador, you can tell there is some kind of mystery and beauty involving all those things. Salvador is unique for bringing together so much beauty, charm and attractions in just one single place. And even when it’s all known and explored, it seems as if the discoveries never cease. The city continues to fascinate and attract: Every sunset, every great meeting, every reunion, every full moon, every pub conversation gains a special meaning in this land. We wish you a very fruitful and successful Congress, and next to that, we invite you to enjoy the beautiful parks and beaches, many historical churches and mansions, and of course the big range of restaurants with a cuisine of irresistible tropical charm!

We are very happy that you are here to experience the enchanting atmosphere of this city that awakens all the senses!

Welcome to Bahia!

Jaldo de Souza Santos
Chair Brazilian Host Committee
President Federal Council of Pharmacy of Brazil

Jean Parrot
President
International Pharmaceutical Federation (FIP)
USA
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The sessions identified in the programme with an * and programme number are cosponsored by ASHP and will be available for continuing education credit for the number of hours indicated. Pharmacists seeking CE credit hours must either complete a CE Request Form online and print their CE Statements or complete the CE Request Paper Form on-site. ASHP will mail validated Statements of Continuing Pharmacy Education to them within six to ten weeks after the Congress. Instructions to process CE online will follow on the next pages.

The Netherlands
An application for accreditation has been submitted to the Royal Dutch Pharmaceutical Society (KNMP).

Portugal
Sessions identified in the programme with * for accreditation and an ACPE programme number will be considered as continuing professional development activities for the professional license revalidation by the Portuguese Pharmaceutical Society (Ordem dos Farmaceuticos). The number of credits (CDPs) attributed to those sessions will be 0,1 CDP per hour.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

USA
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The sessions identified in the programme with an * and programme number are cosponsored by ASHP and will be available for continuing education credit for the number of hours indicated. Pharmacists seeking CE credit hours must either complete a CE Request Form online and print their CE Statements or complete the CE Request Paper Form on-site. ASHP will mail validated Statements of Continuing Pharmacy Education to them within six to ten weeks after the Congress. Instructions to process CE online will follow on the next pages.

The Netherlands
An application for accreditation has been submitted to the Royal Dutch Pharmaceutical Society (KNMP).

Portugal
Sessions identified in the programme with * for accreditation and an ACPE programme number will be considered as continuing professional development activities for the professional license revalidation by the Portuguese Pharmaceutical Society (Ordem dos Farmaceuticos). The number of credits (CDPs) attributed to those sessions will be 0,1 CDP per hour.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

USA
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The sessions identified in the programme with an * and programme number are cosponsored by ASHP and will be available for continuing education credit for the number of hours indicated. Pharmacists seeking CE credit hours must either complete a CE Request Form online and print their CE Statements or complete the CE Request Paper Form on-site. ASHP will mail validated Statements of Continuing Pharmacy Education to them within six to ten weeks after the Congress. Instructions to process CE online will follow on the next pages.

The Netherlands
An application for accreditation has been submitted to the Royal Dutch Pharmaceutical Society (KNMP).

Portugal
Sessions identified in the programme with * for accreditation and an ACPE programme number will be considered as continuing professional development activities for the professional license revalidation by the Portuguese Pharmaceutical Society (Ordem dos Farmaceuticos). The number of credits (CDPs) attributed to those sessions will be 0,1 CDP per hour.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.

China Taiwan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Taiwan Society of Health-System Pharmacists (TSHP). The Taiwanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

France
The HCPC (Haut Comité de la Formation Pharmaceutique Continue) has accredited the same congress sessions as the ACPE. French participants are advised to acquire a Statement of Continuing Education form included in their registration envelopes.

Germany
The congress sessions accredited by ACPE are automatically accredited in Germany, as agreed with the BAK (Bundesapothekerkammer - Federal Chamber of Pharmacists, number BAK 2005/33). The German participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Japan
Those congress sessions accredited by ACPE are recognized as valid continuing education, accredited by the Council on Pharmacists Credentials in Japan. The Japanese participants are advised to acquire a Statement of Continuing Education Credit according to the instructions on the next pages of this programme.

Canada
The Canadian Society of Hospital Pharmacists (CSHP) has accredited the sessions indicated in the programme with an asterisk to its members. The number of CAs for those sessions will be 1 per hour.
### PROGRAMME ATTENDANCE TRACKING FORM

**66th Annual Congress of FIP**  
**World Congress of Pharmacy and Pharmaceutical Sciences**  
**August 25-31, 2006 in Salvador Bahia, Brazil**

**IMPORTANT:**  
This form is for you to track the sessions you attended at the Congress. It will help you in completing your CE Request online at [www.ashp.org/meetings/CERequest/index.cfm](http://www.ashp.org/meetings/CERequest/index.cfm).

Name.............................................................., ASHP Member/Customer ID:...........................

<table>
<thead>
<tr>
<th>CE Sessions</th>
<th>CE Hours Available</th>
<th>CE Hours Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday - Sunday, August 25-27, 2006 (Pre-Satellite Programs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ R1 – Pharmacovigilance and Patient Safety</td>
<td>12.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ R2 – A Risky Journey? Patient Safety From Home to Hospital and Back</td>
<td>8.0 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Monday, August 28, 2006</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P1 – Innovations in Patient Treatment</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G1 – Learning for Practice</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G2 – Managing Change in Pharmacy Practice</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G4 – Reaccreditation – Is First Degree Enough for Life?</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G5 – Community Pharmacy – Advancing Patient Care</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday, August 29, 2006</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P2 – Innovative Healthcare Delivery</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G9 – Web-Originated Consumer Medicines – Where are We Now?</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G10 – International Regulatory Issues for Innovative Medicines</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G11 – Pricing Policy in a Global Market</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G13 – Pharmacists as Advocates of Public Health</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ P-S1 – Combating Counterfeiting (Part I)</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Wednesday, August 30, 2006</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P3 – Using Innovations to Improve Patient Safety</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ P4 – Innovations in Learning and Education</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G6 – Country Specific Approach in Pharmacoepidemiology &amp; Pharmacoeconomics</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G14 – Biosimilars – The Effect on Practice</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G15 – Counselling, Concordance &amp; Communication: Innovative Edn for Pharmacists</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G17 – Training Hospital Pharmacists for the Future</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G18 – Innovations in Pharmacy Practice</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ P-S2 – Combating Counterfeiting (Part II)</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ S6a – Nuclear Pharmacy Practice and Science Workshop (Part I)</td>
<td>6.0 hours</td>
<td></td>
</tr>
<tr>
<td><strong>Thursday, August 31, 2006</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ G20 – Integration of Electronic Patient Health Record</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G21 – YPG Educational Forum: Emerging Trends in Pharmacy</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G22 – Antimicrobial Drug Resistance</td>
<td>3.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ G24 – Patient Care in the 21st Century Marching Forward</td>
<td>6.0 hours</td>
<td></td>
</tr>
<tr>
<td>❑ S6b – Nuclear Pharmacy Practice and Science Workshop (Part II)</td>
<td>6.0 hours</td>
<td></td>
</tr>
</tbody>
</table>

**Remember...**  
Do not submit this form to request CE for these sessions.  
Use it to track sessions you attended.  
Record your CE [www.ashp.org/meetings/CERequest/index.cfm](http://www.ashp.org/meetings/CERequest/index.cfm)  
Print your CE statement immediately online.  
Keep this form for your records.

---

**CONTINUING PHARMACY EDUCATION REQUEST FORM**

**66th Annual Congress of FIP**  
**World Congress of Pharmacy and Pharmaceutical Sciences**  
**August 25-31, 2006 in Salvador Bahia, Brazil**

**PROGRAM INFORMATION**  
To receive continuing pharmacy education credit, please record the hours you attended each session from the list. Return completed form to the staff monitor at the Accreditation Desk. An official ASHP Statement of Continuing Pharmacy Education will be mailed to you within four to six weeks. If you record your CE online, please do not complete this form.

<table>
<thead>
<tr>
<th>CE Sessions</th>
<th>ACPE Program Number</th>
<th>CE Hours</th>
<th>Hours Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday - Sunday, August 25-27, 2006 (Pre-Satellite Programs)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ R1 – Pharmacovigilance and Patient Safety</td>
<td>204-999-06-045-L04</td>
<td>12.0</td>
<td></td>
</tr>
<tr>
<td>❑ R2 – A Risky Journey? Patient Safety From Home to Hospital and Back</td>
<td>204-999-06-047-L04</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td><strong>Monday, August 28, 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P1 – Innovations in Patient Treatment</td>
<td>204-999-06-066-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G1 – Learning for Practice</td>
<td>204-999-06-069-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G2 – Managing Change in Pharmacy Practice</td>
<td>204-999-06-050-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G4 – Reaccreditation – Is First Degree Enough for Life?</td>
<td>204-999-06-051-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G5 – Community Pharmacy – Advancing Patient Care</td>
<td>204-999-06-052-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday, August 29, 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P2 – Innovative Healthcare Delivery</td>
<td>204-999-06-067-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G9 – Web-Originated Consumer Medicines – Where are We Now?</td>
<td>204-999-06-065-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G10 – International Regulatory Issues for Innovative Medicines</td>
<td>204-999-06-055-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G11 – Pricing Policy in a Global Market</td>
<td>204-999-06-056-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G13 – Pharmacists as Advocates of Public Health</td>
<td>204-999-06-057-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ P-S1 – Combating Counterfeiting (Part I)</td>
<td>204-999-06-072-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td><strong>Wednesday, August 30, 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ P3 – Using Innovations to Improve Patient Safety</td>
<td>204-999-06-068-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ P4 – Innovations in Learning and Education</td>
<td>204-999-06-069-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G6 – Country Specific Approach in Pharmacoepidemiology &amp; Pharmacoeconomics</td>
<td>204-999-06-053-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G14 – Biosimilars – The Effect on Practice</td>
<td>204-999-06-058-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G15 – Counselling, Concordance &amp; Communication: Innovative Edn for Pharmacists</td>
<td>204-999-06-059-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G17 – Training Hospital Pharmacists for the Future</td>
<td>204-999-06-060-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G18 – Innovations in Pharmacy Practice</td>
<td>204-999-06-061-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ P-S2 – Combating Counterfeiting (Part II)</td>
<td>204-999-06-073-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ S6a – Nuclear Pharmacy Practice and Science Workshop (Part I)</td>
<td>204-999-06-070-L04</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td><strong>Thursday, August 31, 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>❑ G20 – Integration of Electronic Patient Health Record</td>
<td>204-999-06-062-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G21 – YPG Educational Forum: Emerging Trends in Pharmacy</td>
<td>204-999-06-063-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G22 – Antimicrobial Drug Resistance</td>
<td>204-999-06-064-L04</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>❑ G24 – Patient Care in the 21st Century Marching Forward</td>
<td>204-999-06-065-L04</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td>❑ S6b – Nuclear Pharmacy Practice and Science Workshop (Part II)</td>
<td>204-999-06-071-L04</td>
<td>6.0</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL hours** (44 maximum hours)

**PARTICIPANT INFORMATION**  
ASHIP Member / Customer ID:........................................Name:........................................  
Address:......................................................................................................................................................................................................  
City/State/Zip:......................................................................................................................................................................................................  
Date:............................................................................  
Signature:......................................................................................................................................................................................................  
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  
If you use this form it will take 8-10 weeks to get your CE Statement. Do it online and print your CE statement immediately.
GENERAL EVENTS

Registration
(Pestana Bahia: Fernando Pessoa Foyer, level –1)
The opening hours of the registration desk are:
Saturday 26 August 2006: 07:30 - 17:00
Sunday 27 August 2006: 08:30 - 17:00
Monday 28 August 2006: 08:30 - 17:00
Tuesday 29 August 2006: 08:30 - 17:00
Wednesday 30 August 2006: 08:30 - 17:00
Thursday 31 August 2006: 08:30 - 14:00

Council Meetings
(Pestana Bahia: Fernando Pessoa 3, level –1) (simultaneous translation)
Saturday 26 August 2006 09:00 - 17:00
Thursday 31 August 2006 14:00 - 16:00
With regard to the elections FIP has set up an extra security system in order to ensure that only official representatives from our Member Organisations can be admitted to the Council Meetings. This means that each representative will be asked to submit a written proof when registering, that he/she has been officially appointed to represent his/her organisation.

Opening Ceremony
(Bahiatursa: Centro de Convenções da Bahia)
(shuttle service will be provided; bus schedules will be put up in the Registration Area)
Sunday 27 August 2006 14:00 - 16:00

Assembly of Pharmacists
(Pestana Bahia: Fernando Pessoa 3, level –1)
Monday 28 August 2006 12:00 - 14:00
The Assembly represents a major opportunity for FIP individual members to be involved with policy development within FIP. The FIP President, Jean Parrot, will report on the work of FIP. In particular there will be an opportunity to discuss a number of draft statements being prepared within FIP.

POSTER SESSION

(Pestana Bahia: Gregório de Matos, level –2)
Monday 28 to Wednesday 30 August 2006,
from 09:00 - 16:00
Thursday 31 August 2006 from 09:00 - 14:00

Posters displayed on Monday 28 and Tuesday 29 August 2006
- Hang up poster on Sunday 27 August between 12:00 and 16:00 hours
- Presenters at poster board on Monday 28 and Tuesday 29 August from 12:00-14:00 hours
- Take down poster on Tuesday 29 August at 14:00
- FIP put up new numbers 14:30-16:00

CODES

Academic Pharmacy Section 1-9 AS-P001-P009
Administrative Pharmacy Section 1-8 APS-P001-P008
Clinical Biology Section 1-8 CBS-P001-P008
Industrial Pharmacy Section 1-50 IPS-P001-P050
History of Pharmacy 1-2 HP P001-P002
Laboratories and Medicines Control Services Section 1-11 LMCS-P001-P011
Military and Emergency Pharmacy Section 1-4 MEPS-P001-P004
Pharmacy Information Section 1-30 PIS-P001-P030
SIG: Bioavailability/Bioequivalence 1-20 BB-P001-P020
SIG: Nuclear/Radiologic Pharmacy 1-6 NR-P001-P006
SIG: Pharmaceutical Biotechnology 1-6 PB-P001-P006
SIG: Pharmacoeconomics/Pharmacoepidemiology 1-20 PE-P001-P020
SIG: Quality of Pharmaceuticals 1-17 QP-P001-P017
SIG: Natural Substances 1-17 NS-P001-P017
SIG: Individualized Medicines 1-2 IM-P001-P002

Posters displayed on Wednesday 30 and Thursday 31 August 2006
- Hang up poster on Wednesday 30 August between 08:00 and 09:00 hours
- Presenters at poster board on Wednesday 30 and Thursday 31 August 2006 from 12:00-14:00 hours
- Take down poster on Thursday 31 August at 14:00

EXHIBITION AND SPONSORS

Exhibition
(Pestana Bahia: Jorge Amado, level –2)
Monday 28 to Wednesday 30 August 2006, from 09:00 - 16:00
Thursday 31 August 2006 from 09:00 - 14:00
Our Brazilian hosts have organised an international exhibition at which delegates can review the latest achievements in new equipment, techniques and products. The exhibition gives companies the opportunity to promote their products and services and to meet with community and hospital pharmacists, pharmacy educators, students and senior officials of national and international organisations and governments, all of whom play an important role in the decision to acquire products and services related to the profession.

The International Pharmaceutical Federation and the Brazilian Host Committee wish to thank:

Deutscher Apotheker Verlag - medpharm Scientific Publishers
The Royal Pharmaceutical Society of Great Britain (RPSGB)
SOCIAL EVENTS

Sunday 27 August 2006
Young Pharmacists Group Welcome Dinner
(Location to be announced)

Monday 28 to Thursday 31 August 2006
(Pestana Bahia: Foyer, level –2)
From 10:00 – 11:00 and from 15:00 – 16:00
Coffee Breaks
In the Foyer near the Exhibition and Poster Area, coffee will be served.

Monday 28 August 2006
20:00 – 21:30
Welcome Reception
(Bahia Othon Palace Hotel; shuttle service will be provided; bus schedules will be put up in the Registration area)

Tuesday 29 August 2006
19:00
International Pharmaceutical Students’ Federation/Young Pharmacists Group
International Night
(Location to be announced)

Wednesday 30 August 2006
Woman in Pharmacy Lunch

Wednesday 30 August 2006
Section Dinners
(shuttle service will be provided; bus schedules will be put up in the Registration Area)
Tickets can be purchased at the BLUMAR desk in the Registration Area.

Thursday 31 August 2006
20:00 – 24:00
Adeus Brazil Party
(shuttle service will be provided; bus schedules will be put up in the Registration Area)
FIP and the Brazilian Host Committee have organised a spectacular Adeus Brazil Party near the beach, for an appropriate goodbye to this fabulous host country!
(Casual dress recommended; minimum attendance required.)
Tickets can be purchased at the On Site Registration desk in the Registration Area.

FIP and the Brazilian Host Committee have organised a spectacular Adeus Brazil Party near the beach, for an appropriate goodbye to this fabulous host country!
(Casual dress recommended; minimum attendance required.)
Tickets can be purchased at the On Site Registration desk in the Registration Area.

Administrative Pharmacy Section Dinner
Location: Salvador Dali
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 55,00 per person

Women in Pharmacy Lunch
Location: Pestana Hotel - A Catarineta Restaurant top floor
Date: August 30, 2006
From 12:00 to 14:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 40,00 per person

Clinical Biology / LMCS Section Dinner
Location: Yacht Club left side
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 65,00 per person

Hospital Pharmacy Section Dinner
Location: Galhia
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 65,00 per person

Academic Pharmacy Section Dinner
Location: Porto das Nações
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 55,00 per person

Industrial Pharmacy Section Dinner
Location: Barbacoa
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 55,00 per person

Community Pharmacy Section Dinner
Location: Barbacoa
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 55,00 per person

Pharmacy Information Section Dinner
Location: Yacht Club left side
Date: August 30, 2006
From 20:00 to 22:00
Prices include:
- A three course menu
- wine/beer/soft drinks and coffee
- transportation
- tax
Price: US $ 65,00 per person
Friday 25 and Saturday 26 August 2006 All day

BOCCAGE (Pestana Bahia)

09:00 - 17:00

R 4: PRE-SATELLITE SYMPOSIUM: PHARMACOVIGILANCE AND PATIENT SAFETY
K 1: 204 – 999 – 96 – 845 - L04 (2.0 Contact Hours / 1 CEU)
FIP Pharmacy Information Section
FIP Special Interest Group on Pharmacovigilology/Pharmacoeconomics
Pan American Health Organization
The Uppala Monitoring Centre/WHO Collaborating Centre for International Drug Monitoring

Intended audiences:
Policy makers; health officials; programme managers; pharmacy educators; professional association staff; hospital administrators; quality improvement/assurance staff and pharmacy journalists (i.e., individuals in an active role and not in a policy position to act as programme developers, implementers, and/or “multiplicators,” taking the information presented to establish patient safety programmes and to share the information with additional audiences in their respective countries/work environments)

Programme:
Plenary presentations with small group, interactive “hands-on” experiences. Workshop materials will be made available for participants to take back and use with their respective audiences. As time permits, opportunities will be provided for one-on-one interaction for specific questions and guidance.

Translation:
Plenary session presentations will be simultaneously translated into English, Portuguese and Spanish. Small group discussions will be organized by language with translation services being provided as needed.

Registration:
Separate registration is required, and only possible in addition to a full Congress registration.

Minimum/maximum number of participants: 25-50

Faculty:
Alexandre Dolos, University of Acera Medical School, Ghana
Rosario O’Donnell, Pan American Health Organization, USA
Murilo Freitas Dias, Brazilian Health Surveillance Agency, Brazil
Andrew Gray, University of Kesalado-Natal, South Africa
Keith Johnson, Management Sciences for Health, USA
Sue Olson, The Uppala Monitoring Centre, Sweden
Guilermo Vargas Garcia, University of Navarra, Spain
Carlos Vidotti, Federal Council of Pharmacy, Brazil

Learning objectives:
At the conclusion of this session, the participants should be able to:

- establish pharmacovigilance/patient safety programmes in their respective countries and/or institutions;
- appropriately interpret and apply the information generated by pharmacovigilance programmes;
- apply results of pharmacovigilance programmes to improve patient care outcomes and the public’s health;
- communicate effectively with policy makers and the public on medicine safety;
- educate audiences in their respective countries on pharmacovigilance and patient safety issues.

Agenda:
Session I - Information needs associated with ensuring patient safety; types of reporting, potential for collaboration, and contribution to patient safety; barriers to reporting; identifying and accessing key reference materials to support reporting programmes; quality of evidence; interpreting data in clinical practice; using data for policy and decision making.

Session II - Establishing a patient safety reporting programme; planning and establishing reporting programmes at the national and/or institutional levels; understanding problem-focused reporting for select diseases, patient subgroups, and/or medications, getting stakeholders buy-in, defining what kind of events should be reported, developing and testing reporting forms; promoting the culture of reporting and marketing your programme; capturing data for analysis; understanding the importance of networking with other programmes.

Session III - Getting the most out of data and data analysis; patient safety signals, interpretation, and decision making; data sources, validity, and reliability; aims of and strategies for data mining, safety evaluation after a signal has been received/communicated.

Session IV - Effective communication practices in patient safety; understanding the importance of feedback to stakeholders and system reporters; various courses of action to consider in applying pharmacovigilance findings to patient care and the public health; understanding the basis for and implications of a drug recall; understanding the role of medication labeling in patient safety; mechanisms for alerting prescribers, dispensers, and consumers to patient safety findings; understanding the relevance of and being able to create an ADR alert or management system to provide ongoing safety for the patient; communicating risk information to patients in an effective fashion; crisis management.

Session V - Putting the results of pharmacovigilance activities into public policy and patient care arenas; benefit-risk and cost-benefit analyses; pharmacovigilance and rational use of drugs; minimizing medication errors and the impact of adverse drug reactions; using pharmacovigilance to impact quality of drug products in the marketplace; impacting public policy.

Saturday 26 August 2006, Afternoon

FERNANDO PESSOA (Pestana Bahia)

13:00 - 17:00

R 6: PRE-SATELLITE SYMPOSIUM: CONTINUING EDUCATION PROGRAMME
A RISKY JOURNEY? PATIENT SAFETY FROM HOME TO HOSPITAL AND BACK
217 – 999 – 96 – 845 - L04 (3.0 Contact Hours / 0.8 CEU, total programme)
FIP Community Pharmacy Section
FIP Hospital Pharmacy Section

Separate registration is required, and only possible in addition to a full Congress registration.

Planning Committee:
Rosanna Holland, Pluralistic Consultants, USA (Chair)
James Herborg, Pharmakon, Denmark
Olivier Bugnon, Polyclinique Medicale Universitaire, Switzerland
James McCleary, The Queen’s University of Belfast, UK
Christine Nimmo, American Society of Health-System Pharmacists, USA
Martin Schult, ABDA, Germany
Fope van Mil, Van Mil Consultancy, The Netherlands
Alison Roberts, University of Sydney, Australia
Australian workshop leaders:
Ema Paulino, Portugal
Miguel Angel Gastellurrutia, Spain

Programme description:
During the course of one’s lifetime there is a good chance that any one of us might have to be hospitalised. For some it will be for surgery, others for acute medical treatment or trauma, and for some to treat the adverse effects of medicines. As we all know, hospitalisation is risky terrain. And in this day and age, with more and more patients being discharged sooner and sooner, the responsibility for ongoing care being transferred into the community. In terms of medication management this means that community pharmacists are becoming more and more involved with patients more critically ill than before. But what do pharmacists do thereafter? Is everything essential and communication between hospital and community pharmacists grows in importance. But this works both ways. Consider this: On admission of a patient to hospital, does the hospital pharmacist have a complete picture of the patient’s medications and non-prescribed use? And what is this information actually transferred correctly to the community pharmacist? Is this patient discharge summary a comprehensive list of all the medications that the patient is taking, or has been taking in the past? Much of this information resides in the community pharmacist’s/’patient records. Similarly, when the patient leaves hospital, is the community pharmacist made aware of the discharge treatment? Do they have the diagnosis of the pertinent laboratory results that will assist them in the pharmaceutical care of the patient when they return to the community? If the answer to either of these questions is no, then the patient may be at risk of inadvertent medication misuse. Insofar as medication use safety is a prime concern of pharmacists, no matter where they practice, it is of utmost importance to ensure that we have systems in place to minimise these risks. One way of doing this is to ensure that the interface between community and hospital pharmacy practitioners is fully developed and functional so that risk to patients due to miscommunication or lack of communication is minimised. Accurate and timely information transfer is paramount.

This symposium with its practical workshops provides the opportunities for community and hospital pharmacists to discuss these issues and work together to explore the interface between practices with the objective of providing effective seamless pharmacy care for all patients.

Registration:
At the conclusion of this session, the participants should be able to:
- identify areas of weaknesses in community-hospital pharmacy communications that may place patients at risk;
- discuss ways of overcoming communication problems at the hospital-community pharmacy interface that will maximise seamless patient pharmacovascular care;
- give examples of approaches and strategies that can be put in place to ensure patient medication risk is minimised during transfer from a patient’s place of residence to hospital and back again.

Chair: Rosanna Holland, Community Pharmacy Section, USA
Co-Chair: Lee Vermeulen, Hospital Pharmacy Section, USA

13:00 Welcome and introduction
Rosanna Holland, Pluralistic Consultants, USA and Lee Vermeulen, University of Wisconsin, USA

13:15 Patient safety during transitions from home to hospital and back
Catherine Disguni, Academic Department of Pharmacy, UK
Workshop 1: Issues and concerns - Medication safety for patients in transition
Workshop rooms: Mercado Modulare, 1 and 2; Palacio Hotel; Fete de Bar; Elevador Lacerda (Mercure)

What are the major medication safety considerations when a patient moves from his/her place of residence to a hospital and back? Is there potential for a breakdown in communication in the pharmaceutical care chain? In this workshop several scenarios will be considered in order to explore this possibility and identify weaknesses in current systems. Patients entering and leaving hospitals with issues relating to pain, treatment of infection and anticoagulation will be used as examples.

16:00 Seamless care systems
Neil MacKenzie, Dalhousie University College of Pharmacy, Canada

Sunday 27 August 2006, Morning

FERNANDO PESSOA (Pestana Bahia)

09:00 - 13:00

R 5: PRE-SATELLITE SYMPOSIUM: CONTINUING EDUCATION PROGRAMME
A RISKY JOURNEY? PATIENT SAFETY FROM HOME TO HOSPITAL AND BACK
217 – 999 – 96 – 845 - L04 (3.0 Contact Hours / 0.8 CEU, total programme)
FIP Community Pharmacy Section
FIP Hospital Pharmacy Section

Workshop 2: Patient medication safety: Seamless care - making it happen
Workshop rooms: Mercado Modulare, 1 and 2; Palacio Hotel; Fete de Bar; Elevador Lacerda (Mercure)

What are the major medication safety considerations when a patient moves from his/her place of residence to a hospital and back? Is there potential for a breakdown in communication in the pharmaceutical care chain? In this workshop several scenarios will be considered in order to explore this possibility and identify weaknesses in current systems. Patients entering and leaving hospitals with issues relating to pain, treatment of infection and anticoagulation will be used as examples.

11:00 Integrated medicine management
James McCleary, The Queen’s University of Belfast, UK

13:00 The Australian experience
Rebekah Mokes, University of Sydney, Australia

14:00 Data exchange
Dick Tromp, Quality Institute for Pharmaceutical Care, The Netherlands

16:00 Seamless care systems
Neil MacKenzie, Dalhousie University College of Pharmacy, Canada

Summary and closure

From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks
In the Foyer on Level 2 (near the Exhibition and Poster Area), coffee will be served.

WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES
66th INTERNATIONAL CONGRESS OF FIP
Monday 28 August 2006, Morning

**WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES**

**66th INTERNATIONAL CONGRESS OF FIP**

---

**FERNANDO PESSOA 1 (Pestana Bahia)**

**6:00 - 12:00**

**LEARNING FOR PRACTICE**

- **204 – 999 – 06 – 06 – 1.04 (3.0)** Contact Hours / 1 CEU

**FIP Academic Pharmacy Section**

**International Pharmaceutical Students’ Federation**

**Target audience:** The audience consists of individuals interested in learning about pharmaceutical practice in different settings and contexts.

**Purpose:** The purpose of this activity is to provide a platform for students and practitioners to share their experiences and insights about pharmaceutical practice.

**Learning outcomes:** Participants will be able to:

- **Discuss innovations that have the potential to change the profession of pharmacy**
- **Identify diverse practice settings**
- **Understand the competencies required to deliver professional pharmacy services**
- **Discuss the principles of research-led teaching as they apply to Pharmacy Practice**
- **Understand the role of the pharmacist in clinical assessment**
- **Appreciate the potential role for patients in the education of pharmacists and pharmacy students**
- **Identify diverse practice settings that develop clinical skills in pharmacy students**

**Chair:** Katja Hakkarainen, IPSF, Finland

**Speakers:**

- **Jennifer Marriott,** Monash University, Australia
- **Drummond de Andrade,** Universidad de la Frontera, Chile
- **Loyd Allen,** ISPhC, USA
- **Christine Nimmo,** American Pharmacists Group, South Africa

**Duration:** 6 hours

---

**FERNANDO PESSOA 2 (Pestana Bahia)**

**6:00 - 12:00**

**MANAGING CHANGE IN PHARMACY PRACTICE**

- **204 – 999 – 06 – 06 – 1.04 (3.0)** Contact Hours / 1 CEU

**FIP Community Pharmacy Section**

**Chair:** Eva Terástama, FIP Community Pharmacy Section, Finland

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about managing change in pharmacy practice.

**Learning outcomes:** Participants will be able to:

- **Identify different practice settings**
- **Describe the principles of research-led teaching as they apply to Pharmacy Practice**
- **Understand the role of the pharmacist in clinical assessment**
- **Appreciate the potential role for patients in the education of pharmacists and pharmacy students**
- **Identify diverse practice settings that develop clinical skills in pharmacy students**

**Chair:** Katja Hakkarainen, IPSF, Finland

**Speakers:**

- **Jennifer Marriott,** Monash University, Australia
- **Drummond de Andrade,** Universidad de la Frontera, Chile
- **Loyd Allen,** ISPhC, USA
- **Christine Nimmo,** American Pharmacists Group, South Africa

**Duration:** 6 hours

---

**FERNANDO PESSOA 3 (Pestana Bahia)**

**6:00 - 12:00**

**INDUSTRIAL PHARMACY EDUCATION AND PRACTICE**

- **204 – 999 – 06 – 06 – 1.04 (3.0)** Contact Hours / 1 CEU

**FIP Industrial Pharmacy Section**

**Chair:** Eva Terástama, FIP Community Pharmacy Section, Finland

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about educational and practical aspects of industrial pharmacy.

**Learning outcomes:** Participants will be able to:

- **Identify different practice settings**
- **Describe the principles of research-led teaching as they apply to Pharmacy Practice**
- **Understand the role of the pharmacist in clinical assessment**
- **Appreciate the potential role for patients in the education of pharmacists and pharmacy students**
- **Identify diverse practice settings that develop clinical skills in pharmacy students**

**Chair:** Katja Hakkarainen, IPSF, Finland

**Speakers:**

- **Jennifer Marriott,** Monash University, Australia
- **Drummond de Andrade,** Universidad de la Frontera, Chile
- **Loyd Allen,** ISPhC, USA
- **Christine Nimmo,** American Pharmacists Group, South Africa

**Duration:** 6 hours

---

**DRUMMOND DE ANDRADE (Pestana Bahia)**

**6:00 - 12:00**

**QUALITY ISSUES**

- **FIP Special Interest Group on Quality Pharmaceutics**

**Chair:** Celso Bittencourt, Brasil

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about quality issues in pharmaceutical practice.

**Learning outcomes:** Participants will be able to:

- **Discuss the development of the profession from product to patient orientation**
- **Understand the theory behind changing behaviour and the use of this in practice**
- **Discuss the usefulness of the tools for changing practice**

**Chair:** Loyd Allen, ISPhC, USA

**Speakers:**

- **Philip Schneider,** University of Maryland, USA
- **Atul Mehta,** Mehta Consulting LLC, USA
- **Bill Williams,** University of Texas, USA
- **Rasool Alhomari,** University of Nottingham, UK

**Duration:** 6 hours

---

**ECA DE QUEIROZ (Pestana Bahia)**

**09:00 - 12:00**

**SATELLITE SYMPOSIUM ON PHARMACOPEIONAL COMPOUNDING**

- **First Symposium of the International Society of Pharmaceutical Compounding (ISPSC)**

**Chair:** Loyd Allen, ISPSC, USA

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about pharmaceutical compounding.

**Learning outcomes:** Participants will be able to:

- **Discuss the development of the profession from product to patient orientation**
- **Understand the theory behind changing behaviour and the use of this in practice**
- **Discuss the usefulness of the tools for changing practice**

**Chair:** Loyd Allen, ISPSC, USA

**Speakers:**

- **Philip Schneider,** University of Maryland, USA
- **Atul Mehta,** Mehta Consulting LLC, USA
- **Bill Williams,** University of Texas, USA
- **Rasool Alhomari,** University of Nottingham, UK

**Duration:** 3 hours

---

**MACHADO DE ASSIS (Pestana Bahia)**

**09:00 - 12:00**

**WORKING GROUP: HISTORY OF PHARMACY (PART 1)**

- **Chairs:** Jacques Gervais, France and Leif Eidkyn, Sweden

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about the history of pharmacy.

**Learning outcomes:** Participants will be able to:

- **Discuss the development of the profession from product to patient orientation**
- **Understand the theory behind changing behaviour and the use of this in practice**
- **Discuss the usefulness of the tools for changing practice**

**Chair:** Loyd Allen, ISPSC, USA

**Speakers:**

- **Philip Schneider,** University of Maryland, USA
- **Atul Mehta,** Mehta Consulting LLC, USA
- **Bill Williams,** University of Texas, USA
- **Rasool Alhomari,** University of Nottingham, UK

**Duration:** 3 hours

---

**PELOURINO (Mercure)**

**09:00 - 12:00**

**QUALITY ISSUES**

- **FIP Special Interest Group on Quality Pharmaceutics**

**Chair:** Celso Bittencourt, Brasil

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about quality issues in pharmaceutical practice.

**Learning outcomes:** Participants will be able to:

- **Discuss the development of the profession from product to patient orientation**
- **Understand the theory behind changing behaviour and the use of this in practice**
- **Discuss the usefulness of the tools for changing practice**

**Chair:** Loyd Allen, ISPSC, USA

**Speakers:**

- **Philip Schneider,** University of Maryland, USA
- **Atul Mehta,** Mehta Consulting LLC, USA
- **Bill Williams,** University of Texas, USA
- **Rasool Alhomari,** University of Nottingham, UK

**Duration:** 3 hours

---

**CORAL 1 & 2 (Blue Tree)**

**09:00 - 12:00**

**WORKING GROUP: HISTORY OF PHARMACY (PART 2)**

- **Chairs:** Jacques Gervais, France and Leif Eidkyn, Sweden

**Purpose:** The purpose of this activity is to provide a platform for discussion and sharing of experiences about the history of pharmacy.

**Learning outcomes:** Participants will be able to:

- **Discuss the development of the profession from product to patient orientation**
- **Understand the theory behind changing behaviour and the use of this in practice**
- **Discuss the usefulness of the tools for changing practice**

**Chair:** Loyd Allen, ISPSC, USA

**Speakers:**

- **Philip Schneider,** University of Maryland, USA
- **Atul Mehta,** Mehta Consulting LLC, USA
- **Bill Williams,** University of Texas, USA
- **Rasool Alhomari,** University of Nottingham, UK

**Duration:** 3 hours

---

**From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks** In the Foyer on Level – 2 (near the Exhibition and Poster Area), coffee will be served.
Monday 28 August 2006, Afternoon

WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES

66th INTERNATIONAL CONGRESS OF FIP

From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks In the Foyer on Level – 2 (near the Exhibition and Poster Area), coffee will be served.
Tuesday 29 August 2006, Morning

From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks In the Foyer on Level 2 (near the Exhibition and Poster Area), coffee will be served.

Learning objectives:

At the conclusion of this session, the participants should be able to:

- describe the benefits of web-based medicines information for patients;
- discuss the relationship between consumer medicines information and wider information about conditions;
- list the main reasons why individualised medicines information supports the provision and handling of medicines to patients;
- be easily accessible in a range of different channels and formats;
- focus on special healthcare areas

PI 2: INNOVATIVE HEALTHCARE DELIVERY

204 – 999 – 06 – 054 - L04 (3.0 CEUs)
FIP Board of Pharmaceutical Practice
Supported by an educational grant from IMS

Not only are the various methods of patient treatment altering with new scientific advances but also the very method of administering healthcare is changing fundamentally. This session will examine four areas where traditional values are being eroded and completely new practices and procedures are being developed.

Managing Chair: Thomas Thielke, USA
Co-Chair: Rubia Maria Weffort de Oliveira, Brazil
09:05
The hospital as the centre for healthcare delivery
Tim Chen, Australia
10:35
Traditional and alternative routes in the supply chain
Martin Schulz, Germany
10:35
Break
10:50
Innovations and their effect on healthcare professionals
Steve Hudson, UK
11:25
Are new channels to the patient adding value?
Per Teeren, IMS Health, UK
11:35
Learning objectives:

At the conclusion of this session, the participants should be able to:

- describe what services are and can now be provided in the home setting;
- discuss how the delivery of some care in alternate sites is affecting the hospital;
- list factors resulting in changes in how medicines are distributed from the manufacturer to the pharmacy;
- describe the impact of where care is provided and how medicines are obtained on the healthcare professionals.

PI 1: MEDICATIONS – WHERE ARE WE NOW?

204 – 999 – 06 – 054 - L04 (3.0 CEUs)
FIP Community Pharmacy Section
Chair: Eiva Turrini, FIP
Community Pharmacy Section, Finland
09:05
How can public health benefit from the pharmacist?
Alejandro Gherardi, Pan American Health Organization, Uruguay
10:30
How can pharmacists contribute to improving health?
David Peace, Royal Pharmaceutical Society of Great Britain, UK
10:00
Break
10:15
How can pharmacists contribute to improving health?
Short presentations from selected countries:
10:15
The role of the pharmacist in preparation for pandemics
Warren Meak, Canada
10:45
The role of the pharmacist in public health in France
Isabelle Adenot, France
10:45
How Thai pharmacists can improve people’s health
Suranong Chimwong, Thailand
11:00
The role of the pharmacist in self medication
Arnaldo Zuboli, Brazil
11:15
The role of the pharmacist in public campaigns
Gert Myhøj, Denmark
11:30
The role of the pharmacist in the fight against HIV/AIDS
Mabel Tereza, Zimbabwe
11:45
The role of the pharmacist in public health in Costa Rica
Luis Pastor, Costa Rica
12:00
Pharmaceutical care for hypertensive patients
Otilia Nocić, Uruguay
12:15
Discussion
12:30
Conclusions by the Chair

DRUMMOND DE ANDRADE (Pestana Bahia)

09:00 – 12:00

INTERNATIONAL REGULATORY ISSUES FOR INNOVATIVE MEDICINES

204 – 999 – 06 – 054 - L04 (3.0 CEUs)
FIP Pharmaceutical Information Section
Chair: Albert Welschmeyer, USA
09:05
International regulation and harmonization for innovative medicines
Yves Sellier, France
11:20
Fixed dose combination products for chronic diseases, AIDS, TB and Malaria: Benefits and regulatory challenges
Brenda Wanning, USA
10:15
Break
10:35
Regulatory changes and HIV drugs negotiations in Brazil
Tarcisio Pachus, Brazil
11:10
Healthcare reforms in Mexico and their impact on the regulatory issues
Jaime Kravzov-Jinich, Mexico
11:20
Learning objectives:

At the conclusion of this session, the participants should be able to:

- understand the importance of regulatory barriers for innovations;
- focus on specific healthcare areas where regulations play a pivotal role;
- give an overview of regulatory changes in South America.

MERCADO MODELO 1, 2 & 3 (Mercure)

09:00 – 12:00

BIOTECHNOLOGY

FIP Board of Pharmaceutical Sciences

Co-Chairs: Daan Crommelin, Universiteit, The Netherlands and Lauro Moretto, Faculdade, Brazil
09:05
Introduction
09:05
What are biotechnological drugs?
Antonio Moreira, University of Maryland, USA
09:40
Hormones, vaccines and enzymes from biotech products
Dario Miranda, ANVISA, Brazil
10:15
Break
10:35
Delivery of therapeutic biotech products
Daan Crommelin, Universiteit, The Netherlands
11:10
GMO: Genetically Modified Organisms as source of biotech drugs
Leila Oda, Brazil

PELOURINHO (Mercure)

09:00 – 12:00

INFECTIOUS DISEASES / DIARRHEA

FIP Clinical Pharmacy Section
All lectures in French language
Chair: Bernard Poggi or Alain Mauléon, France
09:00
HIV: Medicines and vaccination in developing countries
Elben Ould Boubain Vall, France
09:40
Respiratory tract infections and chronic bronchitis in Brazilian children
Luis Alan, Brazil
10:15
Break
10:35
All-Doctor Pylor reduced gastric ulcer treatment and eradication? A controversy
Alexandre Del Corso, France
11:10
Round table discussion: Clinical biology quality insurance and security for efficiency in management of diseases
François Memmi, France

TOPAZIO 1 & 2 (Blue Tree)

09:00 – 12:00

FIP MEETING Fédération Pharmaceutique Sudaméricaine
COUNTERFEITING (PART I)

Chair: Toshio Honda, Japan and Carmen Tamayo, Venezuela

14:00 - 16:00
PHARMACISTS AS ADVOCATES OF PUBLIC HEALTH: TOOL OF THE PHARMACY SCHOOL CURRICULUM PREPARE PHARMACISTS FOR A PUBLIC HEALTH ROLE?

FIP Community Pharmacy Section, The Netherlands
Co-Chairs: Gary Smith, University of Maryland, USA and Claire Anderson, University of Nottingham, UK

15:10
Jane Nicholson, FIP Working Group

15:20
José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

15:30
Co-Chairs: Tom Sam, FIP Industrial Pharmacy Section, The Netherlands and José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

14:05
Global perspective

Valeria Reggi, WHO, Switzerland

14:40
Problems and solutions in Brazil

José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

15:15
Break

15:30
FIP anti-counterfeiting activities

Jane Nicholson, FIP Working Group on Counterfeit Medicines, UK

16:10
Government action

Dora Akunyili, National Agency for Food and Drug Administration and Control, Nigeria

Learning objectives:
At the conclusion of this part of the symposium, the participants should be able to:
- outline the problems that the poor quality of counterfeit medicines cause to public healthcare across the world;
- describe the situation of counterfeit medicines in Brazil and the measures being taken to combat the problem locally;
- list the activities that FIP is undertaking globally to combat counterfeiting;
- outline the strategies and actions that governments can take against counterfeiting and discuss their effectiveness.

PHARMABRIDGE MEETING

Pharmabridge aims at strengthening pharmaceutical services in developing (DC) and transitional countries through coordinated support from the pharmacy establishment and individual pharmacists in developed countries. The project even goes beyond this; it also aims at creating links amongst pharmacists worldwide and is supported by the International Pharmaceutical Federation (FIP), its Board of Pharmaceutical Practice (BPP) and the Commonwealth Pharmaceutical Association (CPA). All those interested in the project, be it from developing or developed countries, wanting to establish contacts with colleagues from other countries (or even a specific country) are invited to attend this meeting.

17:00 - 18:00

MERCADO MODELO 1, 2 & 3 (Mercure)

AFRICAN PHARMACEUTICAL FORUM

Annual General Meeting of the APF Chair: Mabel Kiongozi, Zimbabwe

14:00 - 17:00

DOES THE PHARMACY SCHOOL CURRICULUM PREPARE PHARMACISTS AS ADVOCATES OF PUBLIC HEALTH: TOOL OF THE PHARMACY SCHOOL CURRICULUM PREPARE PHARMACISTS FOR A PUBLIC HEALTH ROLE?

14:00 - 17:00

15:10
Jane Nicholson, FIP Working Group

15:20
José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

15:30
Co-Chairs: Tom Sam, FIP Industrial Pharmacy Section, The Netherlands and José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

14:05
Global perspective

Valeria Reggi, WHO, Switzerland

14:40
Problems and solutions in Brazil

José Maldonado, Evidence Soluções Farmacêuticas Ltda, Brazil

15:15
Break

15:30
FIP anti-counterfeiting activities

Jane Nicholson, FIP Working Group on Counterfeit Medicines, UK

16:10
Government action

Dora Akunyili, National Agency for Food and Drug Administration and Control, Nigeria

Learning objectives:
At the conclusion of this part of the symposium, the participants should be able to:
- outline the problems that the poor quality of counterfeit medicines cause to public healthcare across the world;
- describe the situation of counterfeit medicines in Brazil and the measures being taken to combat the problem locally;
- list the activities that FIP is undertaking globally to combat counterfeiting;
- outline the strategies and actions that governments can take against counterfeiting and discuss their effectiveness.
Wednesday 30 August 2006, Afternoon

FERNANDO PESSOA 3 (Pestana Bahia)

14:00 - 17:00
G 14:
BIOSIMILARS - THE EFFECT ON PRACTICE

- Discuss the innovations in patient communication and education
- Discuss the use of new and evolving techniques to detect counterfeit medicines
- Discuss the use of the screening test in the German Minilab and how they may be used at the point of entry of medicines into the country to reduce the importation of substandard medicines
- Understand the new screening system developed in China for the detection of counterfeit medicines
- Discuss the action taken by the pharmaceutical industry to combat counterfeiting in the gathering of intelligence, production of unique formulations, use of secure markers and implementation of secure packaging

Contact Hours / 0.3 CEUs)
204 – 999 – 06 – 069 – L04 (3.0 Contact Hours / 0.3 CEUs)
FIP Board of Pharmaceutical Practice

Chair: Dick Tromp, The Netherlands

Panelists:
- Aquiles Arancibia, Chile
- Peter Kielgast, Denmark
- Dick Tromp, The Netherlands
- Tony Moffat, University of London, UK

ELEVADOR LACERDA (Mercure)

14:00 - 17:00
S 15:
SEMINAR ON GOOD PHARMACY PRACTICE

- Practices and lessons learned
- Marta Vásquez and Mariana Rodríguez, Uruguay
- The FIP GPP project in a wider perspective

14:00 - 17:00
S 16:
NURSING AND PHARMACY PRACTICE AND SCIENCE WORKSHOP (PART I)

- Services provided by pharmacists:
  - Developed and provided by hospital pharmacies
  - Patricia Zálešek, Costa Rica

- Services provided by pharmacists: Provided through a centralized nuclear pharmacy
  - Fugla Vaugias Escamillas, Colombia
  - Sara Weatherman, USA

Contact Hours / 0.3 CEUs
204 – 999 – 06 – 058 – L04 (3.0 Contact Hours / 0.3 CEUs)
FIP Board of Pharmaceutical Sciences
FIP Board of Pharmaceutical Practice

Chair: Frans van der Vaart, FIP Board of Pharmaceutical Sciences

Panelists:
- Dick Tromp, The Netherlands
- Tony Moffat, University of London, UK
- Chris Mungall, Canada
- Patricia Zálešek, Costa Rica

Coffee Breaks
From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks

In the Foyer on Level – 2 (near the Exhibition and Poster Area), coffee will be served.
Thursday 31 August 2006, Morning

**FERNANDO PESSOA 2**
(Pestana Bahia)
09:00 - 12:00
G 20:
**INTEGRATION OF ELECTRONIC PATIENT HEALTH RECORD SYSTEMS INTO THE PHARMACY – PROGRESS AND PROSPERITIES**
204 – 999 – 06 – 062 – 104 (3.0 Contact Hours / 0.3 CEUs)

**FIP Pharmacy Information Section**
Co-Chair: António D’Emanuele, UK, Karina Tellinger, Sweden and Ema Paulino, Portugal

The programme will explore the development of electronic patient health record systems in different countries with a focus on drug information and how the pharmacist can access and interact with the information in these systems. Such systems will have a major impact on the role of the pharmacist, and opportunities and threats will be considered. Good practice and experience will be shared by speakers in different continents.

09:00 The UK model - An ambitious national project, aiming for joined up care
Lindsay McClure, UK

10:35 The Finnish model – Patient medical profiling in Finland - Impact on the pharmacist
Helle Jacobsgaard, Denmark

11:30 The Danish model – Patient medical profiling in Denmark - Impact on the pharmacist
Johan Braas, Australia

11:50 The Australian model – An update on the MediConnect system

**Panel Discussion**

09:00 - 11:00

**Panel Discussion**

**Panelists**

- Michael Gough, FIP Modern Pharmacy Section
- employing the new technologies on the patient,
- discuss the level of access that pharmacists should have to patient health records;
- discuss the implications and impact of the new technologies on the patient, pharmacist and patient-pharmacist relationship;
- discuss the opportunities, obstacles and threats of the new technologies to the pharmacist.

**From 10:00 - 11:00 and from 15:00 – 16:00: Coffee Breaks** In the Foyer on Level – 2 (near the Exhibition and Poster Area), coffee will be served.
FERNANDO PESSOA 2
Pestana Bahia

14:00 - 17:00
G 21*
YFG EDUCATIONAL FORUM: EMERGING TRENDS IN PHARMACY
204 – 999 – 06 – 063 – 0.44 Contact Hours / 0.5 CEUs
FIP Young Pharmacists Group
Chair: Lisa McDevitt, USA
Programme description:
A new forum on various topics of interest to young pharmacists and pharmacy students will be held, including sessions covering the benefit of drug development for rare diseases, social policy, and the role of the pharmacist in the developing world. 

FIP Young Pharmacists Group
Part 1: Drug development and healthcare policies
This first talk will compare and contrast the benefits of drug development for rare diseases versus evidence-based drug development for mass diseases. It will also address individual versus population-based approaches to drug development. The second talk will address issues such as compulsory licensing, price discrimination, intellectual property, and essential medicines using the Brazilian experience as a case study.

João Carapinha, South Africa
Presentation: Collaborative drug therapy management
Countries and will highlight innovative pharmacy practices and will review the role of the pharmacist in the developing world. The second talk will explore the impact of ethical and professional issues on the pharmacy practice. The panelists will address the current status of six current trends in the pharmacy profession.

15:30
Break

Part 2: Emerging roles in pharmacy practice
This segment will focus on various pharmacy practice environments. The first talk will address significant community pharmacy roles including the incorporation of health screenings and provision of preventative medicine from community pharmacies. The second talk will explore pharmacist-physician relationships and describe the development of pharmacist prescribing. The final talk will review the role of the pharmacist in the developing world and will highlight innovative pharmacy practices in various resource-limited environments.

16:30
Questions with Panel of Speakers

16:30
Questions with Panel of Speakers

16:30
Questions with Panel of Speakers

17:00
Closing remarks

BOCCAGE
Pestana Bahia

13:00 – 15:00
FORUM MEETING: A GLOBAL FRAMEWORK FOR QUALITY ASSURANCE OF PHARMACY EDUCATION
International Forum for Quality Assurance of Pharmacy Education
FIP Academic Pharmacy Section
The International Forum for Quality Assurance of Pharmacy Education, under the auspices of the FIP Academic Pharmacy Section, will present the first draft of the Global Framework for Quality Assurance of Pharmacy Education, which seeks to identify and describe the core elements and principles for quality assurance pharmacy education.

Chair: Mike Roosse, International Forum for Quality Assurance of Pharmacy Education, USA

16:00
Opening remarks

16:05
New drug development: What is the best bet?
Bert Leufkens, The Netherlands

16:30
Compulsory licensing: Benefit or detriment?
Albert Wohrheimer, USA

16:45
Counterfeit medications: Impact on the profession
Jane Nicholson, UK

17:00
Break

17:15
The problem of AMR in Africa, Asia, the Pacific region and Latin America
Kathleen Holloway, Switzerland

17:30
Break

17:45
The role of the “disaster relief pharmacist” – The domestic and international activities of the pharmacist in the Japanese Red Cross Society Eiko Matsum, Japanese Red Cross Society Medical Center Tokyo, Japan

18:00
Factors that could improve utilization of pharmacy health personnel on practicing their specialties
Régis Vaillancourt, FIP Military and Emergency Pharmacy Section, Canada

18:15
The domestic and international activities of the pharmacist in the Japanese Red Cross Society Eiko Matsum, Japanese Red Cross Society Medical Center Tokyo, Japan

18:30
Factors that could improve utilization of pharmacy health personnel on practicing their specialties
Régis Vaillancourt, FIP Military and Emergency Pharmacy Section, Canada

18:45
Learning objectives:
At the conclusion of this session, the participants should be able to:
- understand the impact of research in the development of new radiopharmaceuticals and nuclear pharmacy services;
- describe the process, services and advantages of hospital nuclear pharmacy and centralized nuclear pharmacy;
- provide practical knowledge for the initiation of nuclear pharmacy services;
- promote understanding of research in the development of new radiopharmaceuticals and applications in medicine

19:00
Overview on pharmacovigilence
Munir Freitas Dias, ANVISA, Brazil

19:15
Brazil

19:30
Practical aspects of pharmacovigilence
Bert Leufkens, The Netherlands

19:45
WHO perspectives on pharmacovigilence
Alexander Dohos, Ghana
**LOCAL TOURS**

For all tour information and reservations, please visit the BLUMAR desk in the Registration Area.
(Pestana Bahia: Fernando Pessoa Foyer, level –1)

---

**Bahia By Night (With Dinner and Show)**

The show takes place in the 18th century colonial complex Solar do Úniao which had its own church, manor house and slaves quarters in the old stockrooms and is a showcase of the Candomble; the manculelê, a stick and sword dance from the cane fields; the dance of the caboclo, an Amerindian hunting dance; capoeira, a martial art/dance of Angolan origin and the samba de roda, a spinning, swirling version of this exuberant national dance. Dinner can be included upon request.

**Duration:** 3 hours

**Price:** $48.00 per person

---

**Upper City Tour**

We start in the modern suburb of Barra at the mouth of the Bay with its famous lighthouse and make our way slowly by car or coach to the old historical section of town, the Pelourinho area with the largest and the best preserved complex colonial architecture in the Americas. We stroll through the narrow, bustling streets lined with buildings in pastel shades of an age gone by. We visit the church of S. Francisco with its exuberant gold-leafed Baroque interior and the Pelourinho square, the heart of the old town. This tour shows two distinct aspects of Salvador, the new and the old, concentrating on the early expansion of the city.

**Duration:** 4 hours

**Price:** $16.00 per person (Churches taxes not included)

---

**Lower City Tour**

The lower city tour takes us to the quiet waters of the Ilapagipe Peninsula where the first holiday residences were built. Now, a peaceful family district, life moves at a slower pace than the bustling upper city. Fishermen fish from dug out canoes, locals collect shellfish at low tide, schooners are at anchor, all protected by the famous Barracas, with a full infrastructure for a relaxing morning on the shore of the South Atlantic.

**Duration:** 3 1/2 hrs

**Price:** $16.00 per person

---

**Praia do Forte with lunch**

Praia do Forte is a quiet fishing village 80 km north of Salvador and home to some of the best beaches in Bahia. The road to Praia do Forte (Coconut Highway) takes us to the small villages and deserted beaches of the North Coast. We visit the Sapiranga reserve with its restinga vegetation, a delicate ecosystem, which survives on a sandy soil. Lunch in a local restaurant.

**Duration:** 7 hours

**Price:** $50.00 per person

---

**Museum City tour**

A tour of the most interesting museums of the city, each concentrating on very different aspects of Bahia History. Entrance fee to museum included. Visit to the Costa Pinto Museum (a fine collection of colonial furniture, antique jewelry, clusters of gold and silver amulets given to female slaves). Finally, visit to Sacred Art Museum (considered the finest museum of its kind in Brazil, having a vast collection from the 17th to the 18th centuries).

**Duration:** 4 hours (only on Wednesday and Friday)

**Price:** $25.00 per person (taxes included)

---

**Schooner Cruise with lunch**

After our transfer from the hotel, we board a schooner and cruise to one of the 36 islands in this sparkling bay. We take our cruise to the larger Itaparica Island for lunch. After lunch we take a walking tour of the colonial town of Itaparica and visit the mineral water springs with its legendary rejuvenating properties.

**Duration:** 6 hours

**Price:** $48.00 per person

**Minimum attendance:** 25 persons

---

**On the beach**

Leisure time in Salvador revolves around the beach. The coastline is dotted with thatched huts know as barracas, each providing refreshments and snacks, as well as a base for one’s stay at the beach. We visit one of the liveliest barracas, with a full infrastructure for a relaxing morning on the shore of the South Atlantic.

**Duration:** 3 1/2 hrs

**Price:** $16.00 per person

---

**ANNOUNCEMENT**

**PHARMACEUTICAL SCIENCES WORLD CONGRESS**

**3rd World Congress of the Board of Pharmaceutical Sciences of FIP (PSWC2007)**

**Optimizing Drug Therapy: An Imperative for World Health**

**Organisation and Exhibition:** International Pharmaceutical Federation (FIP) in co-operation with EUPES.

**Sponsoring Organisations**

- European Federation for Pharmaceutical Sciences (EUPES)
- American Association of Pharmaceutical Scientists (AAPPS)
- Association de Pharmacie Galénique Industrielle (APGI)
- Academy of Pharmaceutical Sciences of Great Britain (APSB)
- Academy of Pharmaceutical Science and Technology, Japan (APSTJ)
- Australasian Pharmaceutical Science Association (APSA)
- Controlled Release Society (CRS)
- Pharmaceutical Society of Japan (PSJ)

**Supporting organisations**

- International Society for the Study of Xenobiotics
- International Society for Pharmacoepidemiology

**Core topics:**

- Functional Genomics and Proteomics
- Pharmacology
- Medicinal Chemistry, Natural Product Research
- Drug Metabolism and Transport
- Pharmacokinetics and Pharmacodynamics
- Drug Delivery and Pharmaceutical Technology
- Pharmaceutical Analysis and Quality Control
- Clinical Pharmacology and Pharmaco-epidemiology
- Regulatory Affairs

**PRE-SATELLITE SYMPOSIUM**

Pre-satellite symposium for and by Ph.D. students and postdoctoral fellows

**Date:** 19 and 20 April 2007

**Chair organizing committee:** Stefaan De Smedt (Belgium)

**Information pre-satellite symposium:** stefaan.desmedt@Ugent.be

**Information:** congress@fip.org

**Venue:** RAI Congress Centre, Amsterdam, The Netherlands, from 22-25 April 2007
**ADDITIONAL PROGRAMME ITEMS**

**FIP YOUNG PHARMACISTS GROUP (YPG)**  
Sunday 27 August 2006  
Evening  
YPG Welcome Dinner  
(Location TBA)  
Thursday 31 August 2006  
12:00 – 14:00  
YPG Business Meeting  
(Pestana Bahia: Castro Alves, level 1)

**INTERNATIONAL PHARMACEUTICAL STUDENTS’ FEDERATION (IPSF)**  
Tuesday 29 August 2006  
19:00  
IPSF/YPG International Night  
(Location TBA)

**FIP SECTIONS:**  
ACADEMIC PHARMACY SECTION  
Wednesday 30 August 2006  
Evening  
AS Section Dinner  
(for more information: page 13)

**ADMINISTRATIVE PHARMACY SECTION**  
Monday 28 August 2006  
12:00 – 14:00  
APS Executive Committee Meeting  
(Pestana Bahia: Castro Alves, level 1)  
Tuesday 29 August 2006  
12:00 – 13:45  
APS Business Meeting  
(Pestana Bahia: Drummond de Andrade, level –2)

**CLINICAL BIOLOGY SECTION**  
(Pestana Bahia: Drummond de Andrade, level 1)

**COMMUNITY PHARMACY SECTION**  
Friday 25 August 2006  
09:00 – 17:00  
CPS Executive Committee Meeting  
(Pestana Bahia: Eca de Queirzez, level 1)  
Friday 25 August 2006  
13:00 – 17:30  
CPS Planning Committee Meeting  
(Location TBA)  
Tuesday 29 August 206  
17:00 – 17:30  
CPS Reception  
(Location TBA)

**EDUCATION AND RESEARCH**  
Wednesday 30 August 2006  
9:00 – 12:00  
IPS Business Meeting  
(Pestana Bahia: Castro Alves, level 1)

**LABORATORIES AND MEDICINES CONTROL SERVICES SECTION**  
Wednesday 30 August 2006  
18:00  
LMCS Section Dinner  
(for more information: page 13)

**MILITARY AND EMERGENCY PHARMACY SECTION**  
Sunday 27 August 2006  
18:00  
Meet and Greet  
Wednesday 30 August 2006  
All day  
Brazilian Military Host Day  
Evening  
MEPS Section Dinner  
(Location TBA)  
Thursday 31 August 2006  
13:30 – 14:00  
MEPS Business Meeting  
(Pestana Bahia: Drummond de Andrade, level –1)

**MEPS PHARMACY INFORMATION SECTION**  
Monday 28 August 2006  
09:15 – 12:00  
IPS Council Meeting  
(Pestana Bahia: José de Alencar, level 1)  
Tuesday 29 August 2006  
14:00 – 17:00  
IPS Council Meeting  
(Pestana Bahia: José de Alencar, level 1)  
Wednesday 30 August 2006  
13:15 – 14:00  
IPS Business Meeting  
(Pestana Bahia: Fernando Pessoa 2, level –1)  
Wednesday 30 August 2006  
Evening  
IPS Section Dinner  
(for more information: page 13)

**FIP FOUNDATION FOR EDUCATION AND RESEARCH**  
Wednesday 30 August 2006  
09:00 – 12:00  
Good Pharmacy Practice Meeting  
(Mercure: Elevador Lacerda)  
BY INVITATION ONLY

**LIST OF ABSTRACTS**

**Abstracts - Pre-Satellite Symposium CEP: a Risky Journey? Patient Safety from Home to Hospital and Back (R 2)**  
ABS R2-1 – Page 4  
MEDICINES MANAGEMENT AS PATIENTS MOVE BETWEEN HOSPITAL AND COMMUNITY: LEARNING LESSONS FROM SEAMLESS CARE  
C. Dugan

**Abstracts - Using Innovations to Improve Patient Safety (P 3)**  
ABS P3-1 – Page 12  
THE INCREASINGLY IMPORTANT ROLE OF PATIENTS ORGANISATIONS  
R.G. Goncalves

**Abstracts - Innovations in Learning and Education (P 4)**  
ABS P4-1 – Page 15  
THE HOME AS THE CENTRE FOR IMPROVING SEAMLESS CARE  
J.W.F. Van Mil

**Abstracts - Combating Counterfeiting (P-5)**  
ABS P5-1 – Page 7  
THE FUTURE OF DRUG THERAPY AND THE EFFECTS ON PATIENT CARE  
J. Saseen

**Abstracts - Bioequivalence and BCS (S 2)**  
ABS S2-1 – Page 25  
OVERVIEW OF GENERIC DRUG APHRAON PROCESS  
O. Aracibiza

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
BIOTECHNOLOGY DRUGS: HOW ARE THEY DIFFERENT FROM OTHER DRUGS?  
A.R. Moreira

**Abstracts - Biotechnology (S 3)**  
ABS S3-1 – Page 27  
DELIVERY OF THERAPEUTIC BIOTECH PRODUCTS  
D.J.A. Crommelin

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
NEW Educational Tools  
J. De Gue

**Abstracts - Combating Counterfeiting (P-5)**  
ABS P5-1 – Page 17  
COMBATING COUNTERFEIT DRUGS: THE INTERNATIONAL MEDICAL PRODUCT ANTI-COUNTERFEITING TASKFORCE  
V.R. Reggi

**Abstracts - Innovations in Learning and Education (P 4)**  
ABS P4-1 – Page 17  
THE ROLE OF THE INTERNET: THREATS AND OPPORTUNITIES FOR PATIENT SAFETY  
C.A. Caizone

**Abstracts - Nano Technology (S 1)**  
ABS S1 – Page 22  
APPLICATION OF FLUIDBED PROCESSING TECHNOLOGY FOR DRUG DELIVERY  
A. Melia

**Abstracts - Manufacturing challenges (P 2)**  
ABS P2-1 – Page 22  
MANUFACTURING CHALLENGES FOR PRODUCTION OF NANOPARTICLES  
O. Williams

**Abstracts - Biotechnology (S 3)**  
ABS S3-1 – Page 27  
NEW TECHNOLOGIES IN DRUG DELIVERY AND DRUG DEVELOPMENT  
R.L. Williams

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
SEARCH FOR NEW LEAD COMPOUNDS AND DRUGS FROM HIGHER PLANTS  
K.H. Hiestermann

**Abstracts - Biotechnology (S 3)**  
ABS S3-1 – Page 27  
NEW TECHNOLOGIES IN DRUG DELIVERY AND DRUG DEVELOPMENT  
R.L. Williams

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
SEARCH FOR NEW LEAD COMPOUNDS AND DRUGS FROM HIGHER PLANTS  
K.H. Hiestermann

**Abstracts - Manufacturing challenges (P 2)**  
ABS P2-1 – Page 22  
THE INCREASINGLY IMPORTANT ROLE OF PATIENTS ORGANISATIONS  
R.G. Goncalves

**Abstracts - Innovations in Learning and Education (P 4)**  
ABS P4-1 – Page 15  
THE ROLE OF THE INTERNET: THREATS AND OPPORTUNITIES FOR PATIENT SAFETY  
C.A. Caizone

**Abstracts - Combating Counterfeiting (P-5)**  
ABS P5-1 – Page 17  
COMBATING COUNTERFEIT DRUGS: THE INTERNATIONAL MEDICAL PRODUCT ANTI-COUNTERFEITING TASKFORCE  
V.R. Reggi

**Abstracts - Bioequivalence and BCS (S 2)**  
ABS S2-1 – Page 25  
OVERVIEW OF GENERIC DRUG APHRAON PROCESS  
O. Aracibiza

**Abstracts - Manufacturing challenges (P 2)**  
ABS P2-1 – Page 22  
MANUFACTURING CHALLENGES FOR PRODUCTION OF NANOPARTICLES  
O. Williams

**Abstracts - Biotechnology (S 3)**  
ABS S3-1 – Page 27  
DELIVERY OF THERAPEUTIC BIOTECH PRODUCTS  
D.J.A. Crommelin

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
NEW TECHNOLOGIES IN DRUG DELIVERY AND DRUG DEVELOPMENT  
R.L. Williams

**Abstracts - Biotechnology (S 3)**  
ABS S3-1 – Page 27  
DELIVERY OF THERAPEUTIC BIOTECH PRODUCTS  
D.J.A. Crommelin

**Abstracts - Natural Products research (S 4)**  
ABS S4-1 – Page 27  
SEARCH FOR NEW LEAD COMPOUNDS AND DRUGS FROM HIGHER PLANTS  
K.H. Hiestermann